97. Ulcerative colitis Clinical trials / Disease details
Clinical trials : 2,630 / Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03235752 (ClinicalTrials.gov) | February 6, 2018 | 28/7/2017 | Safety and Efficacy of TJ301 IV in Participants With Active Ulcerative Colitis | A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of TJ301 (FE 999301) Administered Intravenously in Patients With Active Ulcerative Colitis | Active Ulcerative Colitis | Drug: TJ301 300mg;Drug: TJ301 600mg;Drug: Placebo | I-Mab Biopharma HongKong Limited | NULL | Recruiting | 18 Years | 70 Years | All | 90 | Phase 2 | Australia;China;Korea, Republic of;Taiwan |